Investor Relations
-
PRELIMINARY ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR 2021
PRELIMINARY ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR 2021
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
-
ANNOUNCEMENT ON PROGRESS OF REPURCHASE OF H SHARES
ANNOUNCEMENT ON PROGRESS OF REPURCHASE OF H SHARES
-
POSITIONS HELD BY CURRENT DIRECTORS AT THE BOARD AND THE BOARD COMMITTEES
CHANGE OF COMPOSITION OF THE REMUNERATION AND ASSESSMENT COMMITTEE
-
CHANGE OF COMPOSITION OF THE REMUNERATION AND ASSESSMENT COMMITTEE
CHANGE OF COMPOSITION OF THE REMUNERATION AND ASSESSMENT COMMITTEE
-
CONTINUING CONNECTED TRANSACTIONS ENTERING INTO THE 2022 WATER ELECTRICITY FRAMEWORK AGREEMENT, THE 2022 LABOUR SERVICES FRAMEWO
CONTINUING CONNECTED TRANSACTIONS ENTERING INTO THE 2022 WATER ELECTRICITY FRAMEWORK AGREEMENT, THE 2022 LABOUR SERVICES FRAMEWORK AGREEMENT AND THE 2022 LEASING ASSETS FRAMEWORK AGREEMENT WITH LIVZON MAB
-
CONTINUING CONNECTED TRANSACTIONS ENTERING INTO THE 2022 WATER ELECTRICITY FRAMEWORK AGREEMENT AND THE 2022 LABOUR SERVICES FRAM
CONTINUING CONNECTED TRANSACTIONS ENTERING INTO THE 2022 WATER ELECTRICITY FRAMEWORK AGREEMENT AND THE 2022 LABOUR SERVICES FRAMEWORK AGREEMENT WITH JOINCARE
-
Overseas Regulatory Announcement
ANNOUNCEMENT ON THE APPROVAL FOR CLINICAL TRIAL OF ALARELIN ACETATE MICROSPHERES FOR INJECTION
-
Next Day Disclosure Return
Next Day Disclosure Return
Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China Tel： 0756-8135888
©2021 Livzon 粤ICP备05025993号 Support：300.cn
Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China
©2021 Livzon 粤ICP备05025993号
Support：300.cn